Central Trust Company’s Sage Therapeutics SAGE Stock Holding History

Central Trust Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40	Closed	-$3K	–	1230
2021 Q1	$3K	Buy	+40	New	+$3.28K	﹤0.01%	1069

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Central Trust Company's SAGE Position: Q2 2021 in Review

Central Trust Company sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 40 shares — an estimated $3K sold.

Central Trust Company first reported a position in SAGE in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Central Trust Company reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Central Trust Company sold 40 Sage Therapeutics shares in Q2 2021, an estimated $3K.
Central Trust Company first reported a position in Sage Therapeutics in Q1 2021 and held it in 1 quarter.
Central Trust Company's Sage Therapeutics position peaked at $3K in Q1 2021.
256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Central Trust Company's 13F filing for Q2 2021, filed 23 Jul 2021.